Skip to content
Important Safety Information Back to Glaukos.com

Connect with a doctor who performs the only FDA-approved cross-linking procedure and can discuss referrals for imaging.

Find a doctor Find an iLink® Provider

AiDetective

Welcome to your ai Detective Assistant

Uncover expert insights on keratoconus, including diagnostic methods, treatment options like corneal
cross-linking, and highlights from iDetective Case Files. Simply ask a question to receive precise, actionable answers designed to enhance patient care.

Note: This tool is intended for healthcare professionals (HCPs) for educational purposes only and cannot address adverse events (AEs). To report suspected adverse reactions, contact Glaukos Corporation at 1-888-404-1644.

The information provided by this chatbot is intended for educational purposes only and is based exclusively on the content available on iDetectives.com. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Glaukos is not responsible for any actions taken based on the information provided by this chatbot. The chatbot’s responses are limited to its pre-approved knowledge base and may not cover all aspects of the topic. Glaukos does not guarantee the completeness or accuracy of the information provided.

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.*1

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, click View Prescribing Information button below to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022.

View Prescribing Information